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We have identified a new human cDNA (y1L amino
acid transporter-1 (y1LAT-1)) that induces system y1L
transport activity with 4F2hc (the surface antigen 4F2
heavy chain) in oocytes. Human y1LAT-1 is a new mem-
ber of a family of polytopic transmembrane proteins
that are homologous to the yeast high affinity methio-
nine permease MUP1. Other members of this family, the
Xenopus laevis IU12 and the human KIAA0245 cDNAs,
also co-express amino acid transport activity with 4F2hc
in oocytes, with characteristics that are compatible with
those of systems L and y1L, respectively. y1LAT-1 pro-
tein forms a '135-kDa, disulfide bond-dependent het-
erodimer with 4F2hc in oocytes, which upon reduction
results in two protein bands of '85 kDa (i.e. 4F2hc) and
'40 kDa (y1LAT-1). Mutation of the human 4F2hc resi-
due cysteine 109 (Cys-109) to serine abolishes the forma-
tion of this heterodimer and drastically reduces the co-
expressed transport activity. These data suggest that
y1LAT-1 and other members of this family are different
4F2 light chain subunits, which associated with 4F2hc,
constitute different amino acid transporters. Human
y1LAT-1 mRNA is expressed in kidney >> peripheral
blood leukocytes >> lung > placenta 5 spleen > small
intestine. The human y1LAT-1 gene localizes at chromo-
some 14q11.2 (17cR ' 374 kb from D14S1350), within the
lysinuric protein intolerance (LPI) locus (Lauteala, T.,
Sistonen, P., Savontaus, M. L., Mykkanen, J., Simell, J.,
Lukkarinen, M., Simmell, O., and Aula, P. (1997) Am. J.
Hum. Genet. 60, 1479–1486). LPI is an inherited autoso-
mal disease characterized by a defective dibasic amino
acid transport in kidney, intestine, and other tissues.
The pattern of expression of human y1LAT-1, its co-
expressed transport activity with 4F2hc, and its chro-
mosomal location within the LPI locus, suggest y1LAT-1
as a candidate gene for LPI.
rBAT and 4F2hc are homologous proteins that induce amino
acid transport in Xenopus oocytes (1, 2). These two proteins are
slightly hydrophobic, which prompted the hypothesis that
rBAT and 4F2hc are subunits or modulators of the correspond-
ing amino acid transporter. This has been supported by several
indirect observations: (i) rBAT and 4F2hc are involved in the
induction of several activities in Xenopus oocytes (3–6); (ii)
these two proteins can be immunodetected or immunoprecipi-
tated as complexes of '125 kDa in the absence of reducing
agents and as two proteins of '85 kDa (4F2hc or rBAT) and
'40 kDa in the presence of reducing agents (7–9); and (iii) in
oocytes, there is a dissociation between the expression of 4F2hc
and rBAT at the plasma membrane and the induction of system
y1L and b0,1 activity, respectively, indicating that this expres-
sion is limited by an endogenous factor (10, 11). We have
recently provided new evidence that the amino acid transport
system y1L has a heterodimeric structure (11). Thus, we have
shown that the y1L activity induced in oocytes by a cysteine-
less mutant of human 4F2hc is also inactivated by membrane-
impermeant thiol-specific reagents, implying that another pro-
tein is required for this function, which would have external
cysteine(s) that are targets of these reagents. Moreover, the
sensitivity to inactivation is increased by reducing conditions
and in 4F2hc mutants in which cysteine 109 has been mutated.
These results indicate that Cys-109 may be linked by a disul-
fide bond to the cysteine target of these agents of the associated
protein.
ASUR4 (Y12716), an adrenal steroid up-regulated cDNA
from Xenopus laevis A6 cells (12) induces an L-type amino acid
transport activity when co-expressed with 4F2hc in oocytes.1
When comparing the amino acid sequence of ASUR4 to protein
data bases, many highly homologous eukaryotic and prokary-
otic amino acid transporter-related proteins are listed within
the amino acids, polyamines, and choline (APC) family of trans-
porters. Among these, and with highest degree of identity (be-
tween 38 and 82% when corresponding protein regions are
compared) to ASUR4, are found its counterpart in human, E16
(Q01650) (13), and in rat, TA1 (Q63016) (14); a human cDNA,
termed KIAA0245 (D87432) (15); five different Caenorhabditis
elegans open reading frames deduced from genomic DNA se-
quence (Z68216, U50308, Z74042, U56963, and U70850) (16);
and a Schistosoma mansoni cDNA, SPRM1 (L25068). In the
same list appeared a yeast high affinity methionine permease,
MUP1 (17) (U40316), and many other prokaryotic amino acid
permeases. ASUR4 showed low, although significant, identity
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(between 26 and 31%) with the mammalian transporters for
cationic amino acids CAT12 and CAT2 (18, 19). Human E16
was first identified from peripheral blood leukocytes and re-
lated to lymphocyte activation (13). Rat TA1 was cloned later
on the basis of its differential expression between hepatoma
cells and normal liver (14). E16, TA1, and ASUR4 cDNA were
first described as proteins 241 amino acids long. The presence
in the data base of a thyroid hormone regulated X. laevis cDNA,
termed IU12 (AF019906) (20), which was 507 amino acid long
and practically identical to ASUR4 (only one amino acid was
different in the corresponding protein region), suggested that
the former three cDNAs were indeed longer. Very recently, F.
Verrey has submitted a new ASUR4 cDNA GenBank entry
(accession number Y12716), which also has 507 amino acids.
Although IU12 and the new entry of ASUR4 still differ in four
disperse amino acids, we can consider that both sequences
correspond to the same gene in Xenopus. We can now assume
that E16 and TA1 are actually longer proteins.
In this study, we have identified a new human member of
this group of amino acid permease-related proteins. This pro-
tein, which we have named y1L amino acid transporter-1
(y1LAT-1) does not induce transport of amino acids in oocytes
when injected alone, but y1L activity is co-expressed when it is
injected with 4F2hc. We demonstrate here that it forms an
heterodimer with 4F2hc linked by disulfide bridges with resi-
due cysteine 109 of human 4F2hc. Its pattern of expression and
its chromosomal localization indicate that this gene could be
responsible for lysinuric protein intolerance (21), an inherited
disorder of cationic amino acid transport.
EXPERIMENTAL PROCEDURES
Oocytes, Injections, and Uptake Measurements—Oocyte origin, man-
agement, and injections were as described elsewhere (1, 2). Defollicu-
lated stage VI X. laevis oocytes were injected with different amounts of
human 4F2hc, human y1LAT-1, human y1LAT-2 (KIAA0245), or X.
laevis IU12 cRNA. Amino acid transport rates obtained with oocytes
injected with water (50 nl) were similar to those of uninjected oocytes
(data not shown). Synthesis of human 4F2hc cRNA (22) was as de-
scribed (11). IU12 was a gift from Shi and co-workers (20), and the
cRNA was obtained by cutting the cDNA, cloned in pBluescript SK2
between the sites XhoI and EcoRI with ApaI and using T3 polymerase.
The open reading frame of y1LAT-1 was obtained from the Integrated
and Molecular Analysis of Genomes and their Expression (IMAGE)
cDNA clone 727811 cloned in the vector pT7T3 between the restriction
sites EcoRI and NotI. To obtain the y1LAT-2 cRNA, because it has a
long 39-untranslated region and is not expressed properly in Xenopus
oocytes, we inserted the open reading frame of KIAA0245 (obtained
from Takahiro Nagase from the Kasuza DNA Research Institute, (15)
and cloned in pBluescript II SK1) in another vector with a shorter 39
tail. Subcloning was done by cutting pBluescript-KIAA0245 with ApaI
and filling with Klenow; the clone was then ethanol-precipitated, cut
again with PstI, and finally ligated into pSPORT1-human rBAT that
had been cut with PstI and Bst1107I. Influx rates of L-[3H]arginine,
L-[3H]leucine were measured in 100 mM NaCl or 100 mM choline Cl
medium at the indicated days after injection and under linear condi-
tions. When presented, the induced uptake was calculated by subtract-
ing uptake values in uninjected oocytes from those of the corresponding
cRNA-injected oocytes.
PCR Amplification and Sequencing—For PCR amplification, first
strand cDNA was synthesized from 5 mg of total RNA purified from
opossum kidney (23) cells using the SuperScript II kit (Life Technolo-
gies, Inc.). Two degenerate forward and reverse primers were designed
based on two highly conserved regions among KIAA0245, IU12, E16,
TA1, and SPRM1 proteins. From region 1 sequence (A/S)REGHLP
(corresponding to residues 347–353 of KIAA0245), a forward 59-C(C/T)-
(C/A)G(C/A/G)GA(G/A)GG(C/G)CA(C/T)CT(G/C/T/A)CC-39 primer (1F)
was synthesized, as well as a reverse (2R) 59-A(T/G)G(A/C)(T/A)(A/G)-
AA(C/G)A(C/A)(C/G)A(C/T)(T/A/G)GG-39 primer deduced from region 2
sequence P(I/V)(V/F)F(I/C)(I/L) (corresponding to residues 429–434 of
KIAA0245). Amplification was carried out in a Perkin-Elmer 9600
thermocycler, and conditions were as follows: hot start of 3 min at 94 °C;
15 cycles of denaturing (94 °C for 25 s), annealing (starting 65–50 °C
lowering 1 °C each cycle for 30 s), and extension (74 °C for 70 s); 25
cycles of denaturing (94 °C for 25 s), annealing (50 °C for 30 s), and
extension (74 °C for 70 s); and a final extension of 4 min at 72 °C.
PCR-amplified DNA fragments with the expected length were sub-
cloned into pGEM-T easy vector (Promega) and sequenced in one direc-
tion. The DNA sequence obtained and all frames of the deduced amino
acid sequences were then compared with DNA and protein sequence
data bases. All sequences carried out in this work were performed in
one or both directions (in the case of clone 727811) with D-Rhodamine
Dye Terminator Cycle Sequencing Ready Reaction (Perkin-Elmer).
Analysis of the sequence reactions was done with an Abi Prism 377
DNA sequencer.
Computer Analysis—Amino acid or nucleotide sequence homology
searching was performed using basic local alignment tool (BLAST) via
on-line connection to the National Center of Biotechnology Information.
The programs BLASTn, BLASTp, and BLASTx were run using default
parameters. Data base searching was done against nonredundant or
dbEST, when searching for nucleotide sequence homology, and versus
nonredundant when comparing to peptide sequences. The clusters of
Expressed Sequence Tag were identified and analyzed with the IMAGE
data base and Telethon Institute of Genetics and Medicine EST assem-
bly machine tool. Multiple nucleotide or amino acid sequence compar-
isons were done with CRUSTALW via on-line connection to the Genome
World Wide Web server (University of Tokyo) and to the Baylor College
of Medicine Search Launcher (University of Texas). Amino acid se-
quence deduction and other sequence analysis were done with Genetics
Computer Group utilities.
The prediction of transmembrane segments of the proteins y1LAT-1,
y1LAT-2, IU12, and SPRM1 was established on the basis of the com-
bination of three criteria: (i) the prediction of transmembrane segments
by the programs of Aloy et al. (23) and TopPred II (24) using the
algorithms of G. von Heijne (25), Goldman, Engelman, and Steitz (26),
and KD (27) to determine the position of hydrophobicity peaks; (ii) the
prediction of a-helix in the predicted secondary structure using a pro-
gram that combines the algorithms of Chou-Fasman and Rose (28); and
(iii) the surface probability and flexibility index plots, according to the
algorithms of Boger (29) and Karplus and Schulz (30), respectively.
Northern Blot Analysis—A human adult poly(A1) membrane con-
taining 12 different tissues, purchased from CLONTECH (Palo Alto,
CA) was used. Insert of clone 727811 was separated from the pT7T3D-
727811 vector with ApaI-NotI digestion. This 2250-bp-long DNA frag-
ment was purified, labeled with [a-32P]dCTP (Amersham) using a ran-
dom oligonucleotide-priming labeling kit (Amersham), and used as a
probe. Hybridization, carried out in Express HybTM Hybridization
solution (CLONTECH), and wash conditions were as recommended by
the manufacturer. To rule out differences in sample loading, the CLON-
TECH membrane was hybridized with human b-actin probe. A nonra-
dioactive fluorescein and anti-fluorescein peroxidase-conjugated anti-
body detection kit was used (Amersham). Hybridization, washes, and
detection conditions were as suggested by the supplier.
Chromosome Mapping—Chromosome mapping was done using the
Stanford Human Genome Center G3 Radiation Hybrid panel (medium
resolution). DNA samples of this panel, along with total genomic DNA
and pT7T3-727811 (used as a positive controls), were PCR-screened for
the presence of the genomic sequences flanked by the primers F7 (59-
GGAAGTTGAAAAGGAAAGC-39) and R7 (59-AAGGAGACAGGAAAT-
TGG-39), which are located at the 39-untranslated region of the cDNA.
PCR amplifications were carried out in a Perkin-Elmer 9600 thermo-
cycler, using 200 mM dNTP, 3 pmol of each primer and DNA Taq
polymerase (Boehringer Mannheim) in PCR buffer. Amplification con-
ditions were as follows: 35 cycles of denaturing (94 °C for 30 s), anneal-
ing (56 °C for 40 s), and extension (74 °C for 30 s). PCR results were
classified as 0 (for no amplification), 1 (for positive amplification), or r
(for uncertain) and submitted to the Radiation Hybrid Mapping E-mail
server at the Stanford Human Genome Center (SHGC). Resulting chro-
mosomal location, referred to a SHGC marker, was obtained automat-
ically via E-mail from this server.
Site-directed Mutagenesis—Construction of the mutants C109S and
C330S of human 4F2hc was as described in Ref. 11.
Immunoprecipitation of Methionine-labeled Proteins from Xenopus
Oocytes—Oocytes were injected with 10 ng of human 4F2hc or C109S
human 4F2hc (CS1) or C330S human 4F2hc (CS2) alone or in combi-
2 The abbreviations used are: CAT, cationic amino acid transporter;
LAT, L amino acid transporter; LPI, lysinuric protein intolerance; IM-
AGE, Integrated and Molecular Analysis of Genomes and their Expres-
sion; SHGC, Stanford Human Genome Center; PCR, polymerase chain
reaction; bp, base pair(s).
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nation with 10 ng of y1LAT-1 cRNA. After 24 h, [35S]methionine (0.5
mCi in 50 nl of water; ICN) was injected, and the oocytes (usually 20
oocytes) were incubated for 48 h at 18 °C in 1 ml of modified Barth’s
solution. Oocytes were then harvested and lysed in a buffer containing
50 mM Tris-HCl, pH 8.0, 120 mM NaCl, 0.5% Nonidet P-40, and 1 mM
phenylmethanesulfonyl fluoride. Extracts were centrifuged twice at
1000 3 g in order to remove the yolk granules. Aliquots of 106 cpm were
rotated overnight at 4 °C with 20 ml of human 4F2hc antibody (Immu-
notech, Marseille, France) previously bound to protein G-Sepharose
(Sigma). The beads were washed five times in a buffer containing 20 mM
Tris-HCl, pH 8.0, 100 mM NaCl, 1 mM EDTA, 500 mM LiCl, and 0.5%
Nonidet P-40 and five times in the same buffer without LiCl. The
resulting immunoprecipitates were heated in sample buffer with or
without 100 mM dithiothreitol for 5 min at 95 °C before gel loading. The
labeled proteins were separated by SDS-polyacrylamide gel electro-
phoresis and visualized by autoradiography after enhancement with 1
M sodium salicylate.
RESULTS
Our goal was to identify any new member of the amino acid
transporter-related family expressed in kidney and potentially
involved in reabsorption of amino acids. For this purpose re-
verse transcription PCR amplification of total RNA from opos-
sum kidney cells (32) was performed. Degenerated primers
were designed on the basis of two highly conserved protein
regions (see under “Experimental Procedures”) revealed after a
multiple amino acid sequence comparison among KIAA0245,
E16, TA1, IU12, and SPRM1 proteins. Electrophoretic analysis
of the PCR showed one band of 228 bp, which was subcloned
into pGEMT-easy vector and amplified in Escherichia coli.
Several clones were then analyzed by sequencing. Nucleotide
sequence of clone b4c2 showed a significant degree of identity
to the amino acid transporter-related proteins when compared,
using BLASTx program, to nonredundant peptide data bases.
Deduced amino acid sequence comparison showed an identity
of 75, 52, 49, 47, and 20% for b4c2 with KIAA0245, IU12, TA1,
E16, and SPRM1, respectively. This high degree of identity
with KIAA0245 suggested that we had cloned a fragment of the
KIAA0245 ortholog cDNA in opossum. To rule out the presence
of other human genes having high homology to KIAA0245, the
coding region sequence of this gene was run as a query with
BLASTn program against dbEST data bases. Flanking 39- and
59-untranslated regions were avoided to minimize the presence
of KIAA0245 EST in the results. We identified an IMAGE EST
cluster (46303) that corresponds to a new unidentified human
gene with a high degree of identity (75%) to KIAA0245. EST
AA393488 (located 59 of this cluster) and EST AA400789 (lo-
cated 39 of this cluster and presenting a poly(A1) tail) are
flanking regions of IMAGE cDNA clone 727811 and comprised
the whole cDNA. We named this clone y1LAT-1 (y1L amino
acid transporter), and KIAA0245 tentatively as a y1LAT-2
because they yielded system y1L amino acid transport activity
when co-injected with 4F2hc in oocytes (see below).
Two direction sequencing of clone 727811 (Fig. 1) showed a
cDNA 2245 bp long. Sequence comparison of the corresponding
region of y1LAT-1 with the opossum b4c2 clone revealed 82 and
81% identity for DNA and protein, respectively. We then as-
sumed that b4c2 clone is a fragment of the corresponding
y1LAT-1 in opossum. The size of the human y1LAT-1 cDNA
corresponds to the transcript seen in Northern blots (see Fig.
5). The first ATG codon lies within a good consensus initiation
sequence (59-CCACC) (33). The open reading frame continues
to the first stop codon (TAA) at base 1820 and codes for a
protein of 511 amino acid residues with a predicted molecular
mass of 55,988 Da. The nucleotide sequence of y1LAT-1 has
been deposited in the GenBank data base (accession number:
AF092032).
Hydrophobicity studies (see under “Experimental Proce-
dures”) show 12 transmembrane domains with both C- and
N-terminal segments intracytoplasmatic, a typical protein
structure similar to some previously reported organic solute
transporters (34–36). There is only one putative N-glycosyla-
tion site underlined in Fig. 1 (Asn-Ala-Ser) between the puta-
tive transmembrane segments VIII and IX. In our prediction
model, this segment is cytoplasmic and cannot be glycosylated.
There are also two putative casein kinase II phosphorylation
sites (threonine 8 and serine 11, located in the putative cyto-
plasmic N-terminal segment) and one putative protein kinase
C phosphorylation site (threonine 96, located intracellularly
between the putative transmembrane segments II and III). A
multiple sequence alignment of the predicted amino acid se-
quence of y1LAT-1, y1LAT-2 (KIAA0245), IU12, E16, and
SPRM1 is shown in Fig. 2. The percentages of identity between
y1LAT-1 and y1LAT-2, E16, IU12, SPRM1, and the yeast
permease MUP1 are 75, 51, 53, 39, and 31%, respectively. The
predicted structural model of these proteins is also very simi-
lar. Only the consensus for the position of the transmembrane
segment III can vary for the proteins presented in Fig. 2. For
y1LAT-1 and y1LAT-2, this segment could be located in the
position indicated in Fig. 2. However, in the case of IU12, the
fragment is displaced 10 amino acids to the C-terminal end,
and in the protein SPRM1, the fragment is moved 5 amino
acids to the N-terminal end. Because 4F2hc is associated with
y1LAT-1 in a disulfide bond-dependent manner (see Fig. 7), we
looked for cysteine residues conserved in these proteins. There
are only two cysteines conserved in all these proteins: cysteine
151 of y1LAT-1, located extracellularly in our structure model
prediction, corresponding to residues 159, 164, and 137 of
y1LAT-2, IU12, and SPRM1, respectively; and cysteine 174,
located in the transmembrane domain IV and corresponding to
residues 182, 187, and 160 of y1LAT-2, IU12, and SPRM1,
respectively. These two cysteines are not conserved in the yeast
permease MUP1.
The human y1LAT-1 gene was chromosome mapped by using
a radiation hybrid panel (see under “Experimental Proce-
dures”) with primers corresponding to the 39-untranslated re-
gion of the y1LAT-1 cDNA. From this screening, we obtained
13 positive, 70 negative and 2 uncertain results. Chromosome
mapping results, obtained from the SGHC server, linked
y1LAT-1, with a logarithm odds score of 10.4, to a distance of
17 cR (374 kb) from the marker SHGC-13532 (D14S1350) lo-
cated at chromosome 14q11.2. When uncertain samples were
submitted as positive, the localization was linked to the T-cell
receptor a chain marker, which lies '150 kb telomeric of
SHGC-13532.
cRNA from y1LAT-1, y1LAT-2, and IU12 was prepared and
injected into oocytes alone or in combination with an equimolar
quantity of human 4F2hc cRNA and tested for transport of
arginine and leucine (50 mM) in the presence or in the absence
(choline) of sodium (100 mM) (Fig. 3). These three proteins do
not induce any amino acid transport activity when injected
alone, but interestingly, they induce different activities when
co-injected with 4F2hc. In the case of y1LAT-1 and y1LAT-2
(KIAA0245), the pattern of induced activity resembles that
described as system y1L (37) (i.e. sodium-independent uptake
of dibasic amino acids and sodium-dependent uptake of some
neutral amino acids). IU12, by contrast, induced an activity
above that of 4F2hc alone, which is compatible with the activity
described as system L (i.e. sodium-independent uptake of neu-
tral amino acids). For y1LAT-1, the induced activity is very
similar to the component of y1L activity induced by 4F2hc
alone, but the level of induction is higher. From 10 independent
experiments, the average fold induction relative to the induc-
tion of 4F2hc alone was 3.8 6 0.9 (range, 2–14-fold). To explain
this increase, we performed kinetic analysis, and from an in-
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dividual experiment, the kinetic parameters showed an in-
crease in Vmax without apparent change in the K0.5 parameter
(4F2hc-induced uptake: K0.5, 55 6 15 mM; Vmax, 18 6 4 pmol of
arginine (choline medium)/15 min per oocyte; 4F2hc plus
y1LAT-1-induced uptake: K0.5, 45 6 18 mM; Vmax, 36 6 5 pmol
of arginine (choline medium)/15 min per oocyte). A further
characterization of this transport activity co-expressed by
y1LAT-1 and y1LAT-2 is in progress.3
To further characterize the uptake activity co-expressed by
y1LAT-1 and 4F2hc, we measured the inhibition of arginine
uptake by different amino acids at a 100-fold excess concentra-
tion (5 mM). As shown in Table I, dibasic amino acids inhibit 50
mM arginine uptake in a sodium-independent manner, but in
contrast, neutral amino acids inhibit more in the presence of
sodium. In order to define better the effect of sodium on the
inhibition by neutral amino acids, the uptake of L-arginine (50
mM) was measured in the presence or absence of sodium and in
the presence of different concentrations of L-leucine (Fig. 4).
These results showed clearly that sodium increased the affinity
of L-leucine. This effect is indistinguishable in 4F2hc alone or3 M. Pineda, R. Estévez, and M. Palacı́n, manuscript in preparation.
FIG. 1. Nucleotide and deduced
amino acid sequence of the y1LAT-1
cDNA. The size of the clone is 2245 bp
and it contains a 59-untranslated region of
268 bp, followed by an open reading frame
of 511 amino acids and a 39-untranslated
region of 423 bp that contains a poly(A)
tail of 38 bp. The stop codon (TAA) is
indicated by one star. The possible poly-
adenylation signal is underlined. The pu-
tative transmembrane domains, deduced
by hydrophobicity analysis (see under
“Experimental Procedures”), are shown in
boldface.
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4F2hc plus y1LAT-1-injected oocytes. All of this is consistent
with the expression of y1L transport activity (38).
The tissue expression of the mRNA corresponding to
y1LAT-1 was examined by Northern blot analysis at high strin-
gency conditions (Fig. 5). The mRNA species of '2.4 kb hybrid-
izes with the y1LAT-1 cDNA. Transcript expression is as fol-
lows: kidney .. peripheral blood leukocytes .. lung .
placenta 5 spleen . small intestine.
Recently (11), we have postulated that residue cysteine 109
of human 4F2hc could be involved in the formation of a disul-
fide bond with a putative membrane protein already present in
the Xenopus oocyte to express system y1L transport activity.
To test whether this is also the case with human y1LAT-1
protein, we performed co-injection experiments with C109S
(CS1) or C330S (CS2) human 4F2hc mutants (Fig. 6). The CS1
mutant injected alone led to a decrease of 56% in the induced
activity compared with the wild type. This agrees with previous
results (11) that showed a Vmax decrease of 50% without
changes in the K0.5 parameter for this mutant. Moreover, CS1
co-injected with y1LAT-1 showed a 74% decrease in transport
expression compared with wild type 4F2hc co-injected with
y1LAT-1. In contrast, the CS2 4F2hc mutant showed no de-
crease in the induced activity when injected alone (similar to
previous results; Ref. 11) or co-injected with y1LAT-1.
In the batch of oocytes used in the experiment shown in Fig.
6, we checked whether y1LAT-1 and 4F2hc proteins could form
a heterodimeric structure via a disulfide bond. This was done
by [35S]methionine labeling and immunoprecipitation using a
monoclonal antibody directed to human 4F2hc (Fig. 7). Under
nonreducing conditions, two 4F2hc-specific protein bands were
detected in 4F2hc-injected oocytes with '85- and '169-kDa
electrophoretic mobilities. A band of '110 kDa was also visible,
but it did not correspond to 4F2hc because it was also detected
after immunoprecipitation of extracts from oocytes co-express-
ing 4F2hc and y1LAT-1 with protein G-Sepharose without
4F2hc antibody. The 85-kDa band corresponds to 4F2hc, as
detected in activated lymphocytes (9). This band is also de-
tected in oocytes not injected with 4F2hc cRNA, suggesting
that Xenopus oocytes express a homologous 4F2hc protein. The
169-kDa band is not visible in reducing conditions or in oocytes
expressing CS1 4F2hc, suggesting that this band might repre-
sent 4F2hc homodimers linked by a disulfide bridge involving
cysteine residue 109. In oocytes co-injected with wild type or
CS2 4F2hc plus y1LAT-1, a new 4F2hc-specific band of '135
kDa appears. Under reducing conditions, this band is drasti-
cally reduced and a new y1LAT-1-specific '40-kDa band ap-
pears (Fig. 7). In contrast, neither the 135- nor the 40-kDa band
is visible, even after very long film exposures, in oocytes co-
injected with CS1 4F2hc and y1LAT-1. This indicates that the
135-kDa band corresponds to a heterodimer of 4F2hc and
FIG. 2. Amino acid sequence comparison of five members of the family of amino acid transporter-related proteins. Multialignment
was done using the program CLUSTALW Sequence Alignment from Baylor College of Medicine. The thin horizontal lines indicate the putative 12
transmembrane domains determined by computer analysis (see under “Experimental Procedures”). The amino acid residues identical to y1LAT-1
sequence are indicated by gray boxes. The solid frame box indicates a potential N-glycosylation site, but according to our membrane topology
prediction, this site is intracellular and cannot be glycosylated. Two cysteine residues conserved in all the proteins presented here are indicated
by a star.
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y1LAT-1, linked by a disulfide bridge involving cysteine 109 of
4F2hc. The 135-kDa band is also visible after very long film
exposures in 4F2hc-injected oocytes and might represent the
association of 4F2hc with a Xenopus y1LAT-1 homologous pro-
tein (data not shown). It is worth mentioning that this band is
the only one that correlates with the induced y1L transport
activity (see Figs. 6 and 7).
DISCUSSION
In this study, we have identified a new member (y1LAT-1) of
a family of amino acid transporter-related proteins also com-
posed in humans by y1LAT-2 (KIAA0245) and E16. We have
characterized the human y1LAT-1 cDNA sequence, chromo-
somal location, and pattern of expression of its mRNA and
demonstrated that when co-expressed with 4F2hc, it yields y1L
amino acid transport activity and forms a disulfide bond-de-
pendent complex with 4F2hc through residue Cys-109 in oo-
cytes. Therefore, y1LAT-1 is a putative light subunit of the
surface antigen 4F2hc. Moreover, we also present human
y1LAT-1 as a strong candidate for the lysinuric protein intol-
erance (LPI) gene.
The surface antigen 4F2 from lymphocytes has been previ-
ously immunoprecipitated as a complex of 125 kDa, which upon
reduction resulted in two protein bands of 85 kDa (the heavy
chain of 4F2 surface antigen, or 4F2hc) and an unidentified
light chain with an electrophoretic mobility of 40 kDa; this light
chain is known to be nonglycosylated and very hydrophobic (9,
FIG. 3. Different co-expressed transport activities with three
members of the family of amino acid transporter-related pro-
teins and 4F2hc. Oocytes were injected with 10 ng of y1LAT-1 (IM-
AGE clone 727811), y1LAT-2 (KIAA0245), or IU12 alone or coinjected
with 10 ng of human 4F2hc. Three days after the injection, the uptake
of 50 mM L-[3H]arginine (Arg) and 50 mM L-[3H]leucine (Leu) in the
presence (1, closed bars) or absence (2, open bars) of 100 mM NaCl was
determined for 5 min. Amino acid uptake (pmol/oocyte 3 5 min) was
calculated by subtracting the uptake in uninjected from that of the
cRNA injected groups. Amino acid uptake in uninjected oocytes was as
follows: (i) L-[3H]arginine uptake: 1.1 6 0.2 (choline medium) and 3.5 6
0.5 (sodium medium); (ii) L-[3H]leucine uptake: 3.1 6 0.6 (choline me-
dium) and 3.8 6 0.4 (sodium medium).
TABLE I
Inhibition of y1LAT-1/4F2hc-induced transport activity by different
amino acids
Uptake was measured at 50 mM arginine concentration in either the
absence (choline medium) or the presence (sodium medium) of 100 mM
sodium and inhibited by different amino acids at a concentration of 5
mM. Each data point is the mean of values obtained in seven oocytes and
expressed as the residual percentage of uptake. Basal values of uptake
(mean 6 S.E.), expressed in pmol/10 min per oocyte, were 32.7 6 2.3
(choline medium) and 43.3 6 3.3 (sodium medium) for y1LAT-1 plus
4F2hc-injected oocytes and 3.4 6 0.2 (choline medium) and 7.8 6 0.5
(sodium medium) for uninjected oocytes.
Inhibitor (5 mM)
Residual arginine (50 mM) uptake
Choline medium Sodium medium
%
Arginine 2 6 0.3 NDa
Lysine 2 6 0.3 1 6 0.2
Ornithine 0 6 0.6 ND
Leucine 48 6 5 3 6 0.9
Isoleucine 43 6 3 16 6 2
Glutamine 73 6 9 15 6 2
Valine 69 6 9 40 6 9
a ND, not determined.
FIG. 4. Inhibition by L-leucine of the y1LAT-1 and 4F2hc co-
expressed transport activity. Three days after injection of 10 ng of
human 4F2hc alone or human 4F2hc plus 10 ng of y1LAT-1, the uptake
of 50 mM L-[3H]arginine in the absence (choline medium) (open squares)
or in the presence (closed squares) of 100 mM sodium was measured for
10 min in the presence of different concentrations of leucine (0, 250 mM,
500 mM, 1 mM, 2.5 mM, 5 mM, and 10 mM). The percentage of the amino
acid residual uptake was calculated by subtracting the uptake of unin-
jected oocytes and dividing by the uptake of 4F2hc alone or 4F2hc plus
y1LAT-1-injected oocytes without leucine in the medium. The basal
values of the uptake of 50 mM L-arginine were 3.4 6 0.2 and 7.8 6 0.5
pmol/10 min for uninjected oocytes in choline or in sodium medium,
respectively, 19.5 6 5.0 and 27.4 6 3.0 pmol/10 min for 4F2hc-injected
oocytes in choline or in sodium medium, respectively, and 32.7 6 2.3
and 43.2 6 3.3 pmol/10 min for 4F2hc plus y1LAT-1-injected oocytes in
choline or in sodium medium, respectively.
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39). We have recently demonstrated that system y1L transport
activity induced by 4F2hc in oocytes requires association, most
probably by disulfide bridges, with a plasma membrane endog-
enous protein (11). Here we demonstrated that human
y1LAT-1 and 4F2hc combine to generate system y1L amino
acid transport activity in oocytes and form a heterodimeric
complex of '135 kDa. Moreover, this complex correlates with
the induction of y1L transport activity by 4F2hc and y1LAT-1
co-expression in oocytes. Interestingly, immunoprecipitation of
the 135-kDa complex and subsequent reduction results in the
appearance of a y1LAT-1-specific '40-kDa protein band. All of
this strongly indicates that human y1LAT-1 is a light chain of
the surface antigen 4F2hc.
Three proteins, y1LAT-1 and y1LAT-2 (present study) and
IU12 (present study, and for the equivalent protein ASUR4 or
the human ortholog E16)2 induce with 4F2hc several amino
acid transport activities in oocytes: system y1L activity for
y1LAT-1 and y1LAT-2, or system L-type for IU12 or E16. This
suggests that at least these three proteins (human y1LAT-1,
y1LAT-2, and E16) might be light subunits of 4F2hc with
associated amino acid transport activities. This is in full agree-
ment with the fact that both y1L and L transport activities
have been associated with the expression of 4F2hc cRNA or
4F2hc-containing mRNA (2, 40–42, 5–6, 43). Interestingly,
y1LAT-1 is expressed in tissues where mRNA-induced y1L
activity has been reported (small intestine, placenta and lung)
(41, 42).4 The final demonstration that y1LAT-1, y1LAT-2, and
E16 are light subunits of the surface antigen 4F2 awaits co-
immunoprecipitation studies from tissue or cell samples.
Our data strongly suggest that the 4F2hc and y1LAT-1 het-
erodimeric complex is linked by a disulfide bridge involving
4F2hc residue cysteine 109. Thus, both 4F2hc-induced (present
study and Ref. 11) and 4F2hc/y1LAT-1-induced system y1L
transport activity is drastically reduced when the 4F2hc resi-
4 R. Estévez and M. Palacı́n, unpublished results.
FIG. 5. Northern blot analysis for y1LAT-1 mRNA in human
tissues. A poly(A) RNA (2 mg per lane) membrane containing 12 dif-
ferent human adult tissues was purchased from CLONTECH. Blots
were probed with 32P-labeled human IMAGE clone 727811 and washed
at high stringency conditions (see under “Experimental Procedures”).
Human y1LAT-1 cDNA hybridizes to a transcript of '2.4 kb and is
expressed predominantly in kidney, leukocytes (from peripheral blood),
lung, placenta, spleen, and total small intestine. Proper quality and
control of loading was substantiated by hybridization with human b-ac-
tin cDNA (CLONTECH), used as a control probe.
FIG. 6. Co-expression defect of mutant C109S (CS1) 4F2 but not
C330S (CS2) 4F2 with y1LAT-1 protein. Oocytes were injected with
10 ng of human 4F2hc, C109S-human 4F2hc (CS1), C330S-human
4F2hc (CS2), and 10 ng of y1LAT-1 cRNA alone or in combination.
Three days after the injection, the uptake of 50 mM L-[3H]leucine in the
presence of 100 mM sodium was measured in the linear region of the
time course. Amino acid uptake was calculated by subtracting the
uptake of uninjected oocytes. Data are the mean 6 S.E. obtained from
the uptake of seven oocytes per group of a representative experiment.
Another experiment gave similar results. The rate of 50 mM
L-[3H]leucine uptake in the presence of sodium in uninjected oocytes
was 2.0 6 0.1 pmol/5 min.
FIG. 7. 4F2hc protein forms a heterodimeric disulfide bond-de-
pendent structure with y1LAT-1 through the Cys-109 residue.
Oocytes from the experiment shown in Fig. 6 were injected with 10 ng
of each different cRNA as indicated. [35S]Methionine labeling and im-
munoprecipitation with a monoclonal h4F2hc antibody (4F2hc mAb)
was performed as described under “Experimental Procedures.” Two
autoradiographs (under nonreducing conditions (no DTT) and under
reducing conditions (1DTT)) from a representative experiment are
shown. Another independent experiment, with higher CS1 expression,
gave similar results.
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due cysteine 109 is mutated to serine. In parallel to this, the
formation of the 4F2hc/y1LAT-1 heterodimer is abolished by
this mutation. This suggests that C109S 4F2hc mutant is able
to form an active transporter heterodimer with y1LAT-1, albeit
with lower efficiency than wild type 4F2hc. Most probably,
weak protein-protein interactions between C109S 4F2hc and
y1LAT-1 are destabilized during detergent solubilization prior
to immunoprecipitation. In favor of this, the 4F2hc-induced
y1L transport activity is not sensitive to b-mercaptoethanol
treatment, even though this increases sensitivity to inactiva-
tion by cysteine-specific reagents (11). Two cysteine residues of
y1LAT-1 (residues 151 and 174) are conserved among the
known full-length protein members of this family. Site-directed
mutagenesis studies are currently in progress to identify the
y1LAT-1 residue involved in the disulfide bridge with the Cys-
109 residue of 4F2hc.
One intriguing question is why y1LAT-1 does not induce
amino acid transport when injected alone in oocytes and why
4F2hc does. One possible explanation is that the exogenous
4F2hc may constitute a functional y1L transporter with a
homologous protein of the y1LAT-1 family already present in
the oocyte. The oocyte would synthesize more y1LAT-1-like
subunits than 4F2hc-like subunits. This would be similar to the
activation of the oocyte catalytic a subunit of the Na1/K1
ATPase by expression of foreign b subunits (44). By analogy to
Na1/K1 ATPase (45, 46), the oocyte y1LAT-1-like subunits
might be present in the endoplasmic reticulum and would be
transported to the plasma membrane when exogenous 4F2hc is
added. In this sense, the y1L activity is already present in the
Xenopus oocyte (2), and we can visualize an immunoprecipi-
tated 4F2hc antibody protein with the same molecular weight
as 4F2hc in uninjected oocytes (Fig. 7).
Structural and functional evidence suggested that rBAT also
associates with an oocyte plasma membrane protein to express
system bo,1-like amino acid transport activity (see under “In-
troduction,” and see Refs. 47 and 48 for recent reviews). There-
fore, it will be interesting to determine whether some of the
members of the transporter-related family can also interact
with the rBAT protein. Preliminary results5 indicate that
y1LAT-1, y1LAT-2, and IU12 do not cause bo,1-like amino acid
transport activity with rBAT in oocytes.
LPI is an autosomal recessive disease in which transport of
the cationic amino acids lysine, arginine, and ornithine is de-
fective. This defect has been localized at the basolateral mem-
branes of epithelial cells in small intestine (49, 50) and in the
renal tubules (51). Simell and co-workers (52) reported that
LPI fibroblast showed a reduced trans-stimulated efflux of
cationic amino acids. Clinical signs of LPI include hyperam-
monemia and episodes of stupor, immunological abnormalities
(53), growth retardation, and muscle hypotonia. Potentially
fatal interstitial lung disease and progressive renal failure may
occur at any age (54). Recently, Lauteala et al. (55) have as-
signed, through linkage analysis of 20 Finnish LPI families, the
LPI gene locus to the proximal long arm of chromosome 14. In
this work, recombination studies placed the locus between
markers D14S72 and MYH7; the phenotype showed the high-
est linkage desequilibrium with marker T-cell receptor a chain
within this locus. Although functional criteria pointed to the
cationic amino acid transporters (hCAT-1 and hCAT-2) as can-
didate genes, linkage studies, using flanking microsatellite
markers, excluded both as the mutated gene in LPI (56). The
human y1LAT-1 gene is a good candidate for LPI: (i) 4F2hc is
expressed at the basolateral membrane of proximal tubule
epithelial cells in the kidney (57). (ii) The y1L activity induced
by 4F2hc in oocytes is an exchanger activity that mediates the
efflux of cationic amino acids and the influx of neutral amino
acids plus sodium (58). This would explain why the efflux and
not the influx (because of the presence of a member of the CAT
family of transporters) is affected. (iii) The expression pattern
of this gene is consistent with the tissues in which some defect
in LPI has been detected (lung, immune system cells, kidney,
and intestine). (iv) Finally, its chromosomal localization is
within the locus of the LPI gene (55). Mutational analysis to
prove this hypothesis is currently in progress.
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10. Chillarón, J., Estévez, R., Samarzija, I., Waldegger, S., Testar, X., Lang, F.,
Zorzano, A., Busch, A., and Palacı́n, M. (1997) J. Biol. Chem. 272,
9543–9549
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9574–9580
23. Aloy, P., Cedano, J., Oliva, B., Avilés, F. X., and Querol, E. (1997) Comput.
Appl. Biosci. 13, 231–234
24. Claros, M. G., and von Heijne, G.(1994) Comput. Appl. Biosci. 10, 685–686
25. von Heijne, G. (1992) J. Mol. Biol. 225, 487–494
26. Engelman, D. M., Steitz, T. A., and Goldman, A. (1986) Annu. Rev. Biophys.
Chem. 15, 321–353
27. Kyte, J., and Doolittle, R. (1982) J. Mol. Biol. 157, 105–132
28. Clotet, J., Cedano, J., and Querol, E. (1994) Comput. Appl. Biosci. 10, 495–500
29. Emini, E. A., Hughes, J. V., Perlow, D. S., and Boger, J. (1985) J. Virol. 55,
836–839
30. Karplus, P. A., and Schulz, G. E. (1985) Naturwissenschaften 72, 212–213
31. Furriols, M., Chillarón, J., Mora, C., Castelló, A., Bertran, J., Camps, M.,
Testar, X., Vilaró, S., Zorzano, A., and Palacı́n, M. (1993) J. Biol. Chem. 268,
27060–27068
32. Mora, C., Chillarón, J., Calonge, M. J., Forgo, J., Testar, X., Nunes, V., Murer,
H., Zorzano, A., and Palacı́n, M. (1996) J. Biol. Chem. 271, 10569–10576
33. Kozak, M. (1991) J. Biol. Chem. 266, 19867–19870
34. Mueckler, M., Morris, H. R., Blench, I., Allard, W. J., Baldwin, S. A., Caruso,
C., Panico, M., Lienhard, G. E., and Lodish, H. F. (1985) Science 229,5 M. Pineda, D. Torrents, and M. Palacı́n, unpublished observations.
Identification and Characterization of y1LAT-132444
941–945
35. Guastella, J., Nelson, N., Nelson, H., Czyzyk, L., Keynan, S., Miedel, M. C.,
Davidson, N., Lester, H. A., and Kanner, B. I. (1990) Science 249,
1303–1306
36. Fei, Y. J., Kanai, Y., Nussberger, S., Ganapathy, V., Leibach, F. H., Romero,
M. F., Singh, S. K., Boron, W. F., and Hediger, M. A. (1994) Nature 368,
563–566
37. Devés, R., Chavez, P., and Boyd, C. A. R. (1992) J. Physiol. 454, 491–501
38. Devés, R., and Boyd, C. A. R. (1998) Physiol. Rev. 78, 487–545
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